Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 2/2009

01-04-2009 | Original Article

UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients

Authors: Masahide Onoue, Tomohiro Terada, Masahiko Kobayashi, Toshiya Katsura, Shigemi Matsumoto, Kazuhiro Yanagihara, Takafumi Nishimura, Masashi Kanai, Satoshi Teramukai, Akira Shimizu, Masanori Fukushima, Ken-ichi Inui

Published in: International Journal of Clinical Oncology | Issue 2/2009

Login to get access
Metadata
Title
UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients
Authors
Masahide Onoue
Tomohiro Terada
Masahiko Kobayashi
Toshiya Katsura
Shigemi Matsumoto
Kazuhiro Yanagihara
Takafumi Nishimura
Masashi Kanai
Satoshi Teramukai
Akira Shimizu
Masanori Fukushima
Ken-ichi Inui
Publication date
01-04-2009
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 2/2009
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-008-0821-z

Other articles of this Issue 2/2009

International Journal of Clinical Oncology 2/2009 Go to the issue

Review Article

Contributions of meta-analyses based on individual patient data to therapeutic progress in colorectal cancer

Original Article

Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene

Case Report

Extremely acute exacerbation of interstitial pneumonia after interferon-alpha treatment for metastatic renal cell carcinoma

Case Report

An atypical extrahepatic metastasis of the distal phalanx from hepatocellular carcinoma

Review Article

Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials

Review Article

Efficacy of adjuvant chemotherapy using tegafur-based regimen for curatively resected gastric cancer: update of a meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits